Genmab A/S (GNMSF)
USD 205.1
(7.31%)
USD 205.1
(7.31%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 35.28 Billion DKK | 16.55% |
| 2022 | 30.27 Billion DKK | 22.95% |
| 2021 | 24.62 Billion DKK | 16.48% |
| 2020 | 21.14 Billion DKK | 39.61% |
| 2019 | 15.14 Billion DKK | 78.99% |
| 2018 | 8.46 Billion DKK | 28.14% |
| 2017 | 6.6 Billion DKK | 26.05% |
| 2016 | 5.23 Billion DKK | 34.23% |
| 2015 | 3.9 Billion DKK | 36.13% |
| 2014 | 2.86 Billion DKK | 65.56% |
| 2013 | 1.73 Billion DKK | 2.28% |
| 2012 | 1.69 Billion DKK | 8.21% |
| 2011 | 1.56 Billion DKK | -36.96% |
| 2010 | 2.48 Billion DKK | 11.71% |
| 2009 | 2.22 Billion DKK | -31.83% |
| 2008 | 3.25 Billion DKK | -17.68% |
| 2007 | 3.95 Billion DKK | 119.37% |
| 2006 | 1.8 Billion DKK | 31.68% |
| 2005 | 1.37 Billion DKK | 7.75% |
| 2004 | 1.27 Billion DKK | 7.78% |
| 2003 | 1.18 Billion DKK | -25.46% |
| 2002 | 1.58 Billion DKK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 36.68 Billion DKK | 3.94% |
| 2024 Q2 | 38.61 Billion DKK | 5.29% |
| 2023 Q2 | 31.97 Billion DKK | 5.21% |
| 2023 Q1 | 30.39 Billion DKK | 0.38% |
| 2023 Q4 | 35.28 Billion DKK | 0.14% |
| 2023 FY | 35.28 Billion DKK | 16.55% |
| 2023 Q3 | 35.23 Billion DKK | 10.19% |
| 2022 Q2 | 27.47 Billion DKK | 10.28% |
| 2022 Q3 | 30.68 Billion DKK | 11.68% |
| 2022 Q4 | 30.27 Billion DKK | -1.33% |
| 2022 Q1 | 24.91 Billion DKK | 1.17% |
| 2022 FY | 30.27 Billion DKK | 22.95% |
| 2021 Q1 | 22.21 Billion DKK | 5.05% |
| 2021 Q2 | 22.48 Billion DKK | 1.23% |
| 2021 Q3 | 23.98 Billion DKK | 6.68% |
| 2021 Q4 | 24.62 Billion DKK | 2.68% |
| 2021 FY | 24.62 Billion DKK | 16.48% |
| 2020 FY | 21.14 Billion DKK | 39.61% |
| 2020 Q1 | 15.3 Billion DKK | 1.05% |
| 2020 Q2 | 20.68 Billion DKK | 35.16% |
| 2020 Q3 | 21.52 Billion DKK | 4.06% |
| 2020 Q4 | 21.14 Billion DKK | -1.76% |
| 2019 Q3 | 13.33 Billion DKK | 48.49% |
| 2019 Q4 | 15.14 Billion DKK | 13.61% |
| 2019 FY | 15.14 Billion DKK | 78.99% |
| 2019 Q2 | 8.97 Billion DKK | 2.78% |
| 2019 Q1 | 8.73 Billion DKK | 3.24% |
| 2018 Q2 | 7.19 Billion DKK | 6.14% |
| 2018 Q1 | 6.78 Billion DKK | 2.73% |
| 2018 FY | 8.46 Billion DKK | 28.14% |
| 2018 Q4 | 8.46 Billion DKK | 14.28% |
| 2018 Q3 | 7.4 Billion DKK | 2.83% |
| 2017 FY | 6.6 Billion DKK | 26.05% |
| 2017 Q3 | 5.89 Billion DKK | -2.21% |
| 2017 Q4 | 6.6 Billion DKK | 12.01% |
| 2017 Q2 | 6.02 Billion DKK | 11.52% |
| 2017 Q1 | 5.4 Billion DKK | 3.19% |
| 2016 Q4 | 5.23 Billion DKK | 20.33% |
| 2016 Q3 | 4.35 Billion DKK | 5.44% |
| 2016 Q2 | 4.12 Billion DKK | 5.55% |
| 2016 Q1 | 3.91 Billion DKK | 0.22% |
| 2016 FY | 5.23 Billion DKK | 34.23% |
| 2015 Q2 | 3.28 Billion DKK | 3.42% |
| 2015 Q1 | 3.17 Billion DKK | 10.76% |
| 2015 FY | 3.9 Billion DKK | 36.13% |
| 2015 Q4 | 3.9 Billion DKK | 11.47% |
| 2015 Q3 | 3.5 Billion DKK | 6.62% |
| 2014 Q1 | 2.79 Billion DKK | 61.22% |
| 2014 Q4 | 2.86 Billion DKK | 1.26% |
| 2014 Q2 | 2.71 Billion DKK | -2.64% |
| 2014 Q3 | 2.83 Billion DKK | 4.16% |
| 2014 FY | 2.86 Billion DKK | 65.56% |
| 2013 Q2 | 1.67 Billion DKK | -4.49% |
| 2013 FY | 1.73 Billion DKK | 2.28% |
| 2013 Q4 | 1.73 Billion DKK | -3.64% |
| 2013 Q3 | 1.79 Billion DKK | 7.22% |
| 2013 Q1 | 1.75 Billion DKK | 3.65% |
| 2012 FY | 1.69 Billion DKK | 8.21% |
| 2012 Q1 | 1.45 Billion DKK | -6.7% |
| 2012 Q2 | 1.41 Billion DKK | -2.86% |
| 2012 Q3 | 1.77 Billion DKK | 24.99% |
| 2012 Q4 | 1.69 Billion DKK | -4.47% |
| 2011 Q4 | 1.56 Billion DKK | -6.48% |
| 2011 Q2 | 2.05 Billion DKK | -6.8% |
| 2011 FY | 1.56 Billion DKK | -36.96% |
| 2011 Q1 | 2.2 Billion DKK | -11.24% |
| 2011 Q3 | 1.67 Billion DKK | -18.51% |
| 2010 Q3 | 2.45 Billion DKK | 25.75% |
| 2010 Q1 | 2.08 Billion DKK | -6.31% |
| 2010 FY | 2.48 Billion DKK | 11.71% |
| 2010 Q2 | 1.95 Billion DKK | -6.07% |
| 2010 Q4 | 2.48 Billion DKK | 0.95% |
| 2009 FY | 2.22 Billion DKK | -31.83% |
| 2009 Q4 | 2.22 Billion DKK | 0.0% |
| 2008 FY | 3.25 Billion DKK | -17.68% |
| 2007 FY | 3.95 Billion DKK | 119.37% |
| 2006 FY | 1.8 Billion DKK | 31.68% |
| 2005 FY | 1.37 Billion DKK | 7.75% |
| 2004 FY | 1.27 Billion DKK | 7.78% |
| 2003 FY | 1.18 Billion DKK | -25.46% |
| 2002 FY | 1.58 Billion DKK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioxytran, Inc. | 137.63 Thousand USD | -25638895.045% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -90740.992% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -46217517.938% |
| SQZ Biotechnologies Company | 107.18 Million USD | -32822.836% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -2464160.575% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -334266.117% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -27001.449% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -48765187.086% |
| Marizyme, Inc. | 22.01 Million USD | -160194.707% |
| Genus plc | 1.02 Billion USD | -3329.779% |
| Pharming Group N.V. | 462.85 Million USD | -7524.218% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -1065063.664% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -7071291.214% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -5628129.665% |
| ContraFect Corporation | 20.67 Million USD | -170551.385% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -9233579.682% |
| IMV Inc. | 31.33 Million USD | -112522.837% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -851053.226% |
| ONE Bio Corp. | 70.08 Million USD | -50251.353% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -27360.12% |
| Mesoblast Limited | 667.9 Million USD | -5183.571% |
| MultiCell Technologies, Inc. | 126.22 USD | -27958326631.104% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -100212.687% |
| Genscript Biotech Corporation | 3.38 Billion USD | -942.085% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -4579057.172% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -13506255.324% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -488683.425% |
| Biomind Labs Inc. | 73.81 Thousand USD | -47804665.711% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -2435567.633% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -117471.402% |
| Skye Bioscience, Inc. | 11.94 Million USD | -295442.591% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -2597825.576% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -1284848.85% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -9039877.867% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -1802024.31% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -5132949.982% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -3755291.411% |
| EV Biologics, Inc. | 431.71 Thousand USD | -8174061.598% |
| Q BioMed Inc. | 3.51 Million USD | -1003706.837% |
| GB Sciences, Inc. | 103.44 Thousand USD | -34114669.629% |
| Alpha Cognition Inc. | 2.45 Million USD | -1438992.722% |
| CSL Limited | 38.02 Billion USD | 7.188% |
| Agentix Corp. | 261.39 Thousand USD | -13500313.173% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -7806.855% |
| Enzolytics Inc. | 361.7 Million USD | -9656.25% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 8.11 Million USD | -434761.368% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -1879093.559% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -1355502.882% |
| argenx SE | 4.54 Billion USD | -676.87% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -126184.712% |
| HST Global, Inc. | 1526.00 USD | -2312516282.7% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -73878.03% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -3571780.437% |
| Halberd Corporation | 10.13 Thousand USD | -348326817.382% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -5516771.568% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -394227.733% |
| Zenith Capital Corp. | 7410.00 USD | -476234717.814% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -154905303.626% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -10965823.569% |
| AVAX Technologies, Inc. | 7.37 Million USD | -478255.009% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -13501759.476% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -3802753.784% |
| Ember Therapeutics, Inc. | 184.00 USD | -19178804247.826% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -56690878.023% |
| Helix BioMedix, Inc. | 3.02 Million USD | -1166445.348% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -66860.779% |
| Kadimastem Ltd | 2.3 Million USD | -1531487.445% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -242264.662% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -61808496.35% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -1527662237.662% |
| LadRx Corporation | 2.3 Million USD | -1528964.311% |
| Cell Source, Inc. | 195.17 Thousand USD | -18080967.372% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -7343253.65% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -9979341.034% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -9979341.034% |
| Affymax, Inc. | 7.44 Million USD | -474023.337% |
| Mobile Lads Corp. | 52.00 USD | -67863461438.462% |
| Itoco Inc. | 1.4 Million USD | -2520413.231% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -36891084.127% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -33291409.434% |
| International Stem Cell Corporation | 5.39 Million USD | -654612.43% |
| CytoDyn Inc. | 11.13 Million USD | -316791.164% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -24682355.306% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -197365671.812% |
| Qrons Inc. | 420.00 USD | -8402142757.143% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -9154674.289% |
| SYBLEU INC | 330.46 Thousand USD | -10678392.32% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -6391445.316% |
| Rebus Holdings, Inc. | 5000.00 USD | -705779900.0% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -8619124.175% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -235131.302% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -212753.61% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -44669520.253% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -4081077.133% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -469355.9% |
| Neutra Corp. | 2851.00 USD | -1237776118.871% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -108796.501% |
| PureTech Health plc | 693.97 Million USD | -4985.068% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -437127.244% |
| IXICO plc | 15.84 Million USD | -222629.21% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -425992.731% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -34053.73% |
| CSL Limited | 38.02 Billion USD | 7.188% |
| Cellectis S.A. | 333.99 Million USD | -10465.739% |